nach oben

Erschienen in:

14.09.2020 | Letter to the Editor

Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?

verfasst von: Michela Palleschi, Emanuela Scarpi, Chiara Casadei

Einloggen, um Zugang zu erhalten

Excerpt

We have read the recently reported article by Desmedt et al. published in Journal of Clinical Oncology. …

Desmedt C, Fornili M, Clatot F et al (2020) Differential benefit of adjuvant docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index. J Clin Oncol. https://doi.org/10.1200/JCO.19.01771CrossRefPubMed

Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798–804. https://doi.org/10.1001/jamaoncol.2018.0137CrossRefPubMedPubMedCentral

Shachar SS, Deal AM, Weinberg M et al (2017) Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin Cancer Res 23:3537–3543. https://doi.org/10.1158/1078-0432.CCR-16-2266CrossRefPubMedPubMedCentral

Titel: Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?
verfasst von: Michela Palleschi
Emanuela Scarpi
Chiara Casadei
Publikationsdatum: 14.09.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05923-9

24.04.2024 | DGIM 2024 | Nachrichten

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten